Opinion|Videos|February 18, 2025
Emerging Data on BTK Inhibitor Degraders and Bispecifics in R/R CLL: Updated Results at ASH 2024
Panelists discuss how novel Bruton tyrosine kinase (BTK) degraders like NX-5948 and BGB-16673 are showing promising early clinical activity in relapsed/refractory chronic lymphocytic leukemia (R/R CLL) based on ASH 2024 data, while bispecific antibodies such as epcoritamab from the EPCORE CLL-1 trial represent another emerging therapeutic approach, though longer follow-up is needed to fully understand their optimal role in the treatment landscape.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- There’s been a lot of emerging data with the BTK degraders in R/R CLL. Dr Kahl, what are your perspectives/insights on novel agents like NX-5948?
- What are your thoughts on agents like BGB-16673?
- Another exciting class is bispecifics in R/R CLL. Can you share the updated results with epcoritamab from the EPCORE CLL-1 trial?
Advertisement
Related to this article
Experts break down key melanoma data and trends from the 2026 ESMO Congress.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Durvalumab plus BCG is now an approved first-line option for high-risk NMIBC, but better BCG delivery and biomarker-guided selection should shape its use.
The FDA has approved amivantamab and hyaluronidase-lpuj for metastatic head and neck squamous cell carcinoma.
A UCLA-led study suggests routine mammograms or other breast imaging may not benefit women after double mastectomy for DCIS.
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Are we ready to “take that fork in the road” and move palliative/supportive care into routine cancer care?
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
4
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
5